Poor Prognosis for Women With Pregnancy-Associated Melanoma

This article originally appeared here.
Share this content:
Poor Prognosis for Women With Pregnancy-Associated Melanoma
Poor Prognosis for Women With Pregnancy-Associated Melanoma

MONDAY, March 21, 2016 (HealthDay News) -- For women aged younger than 50 years, melanoma prognosis is worse for those aged 40 to 49 years and for those diagnosed with a pregnancy-associated melanoma, according to a study published in the April issue of the Journal of the American Academy of Dermatology.

Alejandra Tellez, M.D., from the Cleveland Clinic, and colleagues conducted a retrospective study to examine histopathology, staging, risk factors, and outcomes of cutaneous melanoma in women aged up to 49 years with biopsy-proven melanoma.

The researchers identified 462 patients with cutaneous melanoma (mean age, 34.7 years). Women aged 19 years or younger less frequently had invasive melanoma (P < 0.0008). Women aged 40 to 49 years had higher positive sentinel node status (P < 0.008), recurrence rates, metastatic disease (P < 0.001), and death rates (P < 0.008). Significantly worse prognosis was seen for the 41 women with a pregnancy-associated melanoma compared with control non-pregnant patients, with nine-, seven-, and five-fold increases in recurrence (P < 0.001), metastasis (P = 0.03), and mortality (P = 0.06), respectively.

"The increasing incidence of melanoma for women younger than 50 years suggests that regular skin checks and self-examinations are warranted," the authors write. "In addition, in women given the diagnosis of melanoma during or within one year after childbirth, regular follow-up and monitoring for recurrence are recommended."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »